Multicenter Analytical Comparison of Automated Quantitative Assays Versus Line Immunoassay for Anti‐Ro/La Antibody Detection in Primary Sjögren’s Syndrome
Open Access
- 1 January 2026
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , e9771858
Abstract
Objective: This multicenter study aimed to analytically compare the performance of automated quantitative assays—chemiluminescence immunoassay (CLIA) and multiplexed bead immunoassay (MBI)—for detecting anti‐Ro/La antibodies in Chinese patients with primary Sjögren’s syndrome (pSS), compared to line immunoassay (LIA) that is most commonly used in China. Methods: Based on the Chinese Sjögren’s Syndrome Collaborative Research Group, serum samples from 434 patients with pSS and 100 healthy controls were analyzed using LIA, CLIA, and MBI. Sensitivity, specificity, and qualitative agreement were assessed. Receiver operating characteristic (ROC) analysis was carried out to compare the analytical accuracy among assays in detecting anti‐Ro/La antibodies, and the DeLong test was used to compare areas under curves (AUCs). Results: High specificity (95% to 100%) was observed in these assays, and LIA demonstrated the highest sensitivity for anti‐Ro60 (92.6%) and anti‐Ro52 (89.2%). CLIA and MBI exhibited comparable sensitivity to LIA for anti‐La (50.9% vs. 50.2% vs. 48.2%). Qualitative agreement among assays was good for anti‐Ro60 ( κ : 0.84–0.93) and moderate for anti‐La ( κ : 0.74–0.86). MBI achieved the highest AUC values for anti‐Ro60 (0.980), anti‐Ro52 (0.970), and anti‐La (0.935), outperforming CLIA and LIA ( p < 0.05). Conclusion: Automated assays (CLIA and MBI) demonstrate high specificity and analytical accuracy for anti‐Ro/La antibody detection in pSS. MBI achieved the highest accuracy, whereas LIA showed superior sensitivity for anti‐Ro60/52 detection. CLIA provided reliable specificity but failed to detect anti‐Ro52 in this study. Collectively, these findings indicate that CLIA and MBI may represent reliable alternatives to LIA, although validation in disease‐controlled cohorts is required before clinical implementation.Keywords
Funding Information
- Shenzhen Science and Technology Innovation Program (JCYJ20240813104215020)
- National Natural Science Foundation of China (81971464)
- National Key Research and Development Program of China (2019YFC0840603)
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2017-I2M-3-001)
This publication has 39 references indexed in Scilit:
- Anti-Ro/SSA and anti-La/SSB autoantibodies in the tear fluid of patients with Sjogren's syndromeBritish Journal of Ophthalmology, 2004
- Diagnostic associations in a large and consecutively identified population positive for anti-SSA and/or anti-SSB: the range of associated diseases differs according to the detailed serotypeAnnals of the Rheumatic Diseases, 2002
- Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue diseaseAnnals of the Rheumatic Diseases, 2002
- Kappa coefficients in medical researchStatistics in Medicine, 2002
- Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupAnnals of the Rheumatic Diseases, 2002
- Autoantibodies to Extractable Nuclear Antigens: Making Detection and Interpretation More MeaningfulClinical and Vaccine Immunology, 2002
- Multiplexed particle-based flow cytometric assaysJournal of Immunological Methods, 2000
- DETECTION OF ANTI-Ro(SSA) ANTIBODIES IN AUTOIMMUNE DISEASES: COMPARISON OF FIVE METHODSRheumatology, 1993
- Ro ribonucleoprotein assembly in vitroJournal of Molecular Biology, 1992
- Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric ApproachBiometrics, 1988